Following its proposed LabAnswer acquisition, Accenture will form a scientific informatics service division, which it said will enable new patient treatments with “new insights into human biology.”
3D printing, augmented reality and deep learning algorithms will shape the future of the pharmaceutical supply chain says Dr Bertalan Mesko, the Medical Futurist.
Marken has launched a new hybrid logistics service that leverages UPS’ existing global transportation network – including airports, pilots, and aircraft.
Chiltern has acquired Integrated Development Associates Co. Ltd. (IDA), a Japenese contract research organization (CRO) with offices in Japan, Korea, and Southeast Asia.
Patient-operated mobile technology will be demanded on all clinical trials, says mProve, as the industry undergoes an evolution and embraces digital health solutions.
Cure Pharmaceutical has submitted a patent application for an oral film delivery technology it says can combine several active pharmaceutical ingredients without negative interaction.
Non-profit organisations have challenged the proposed addition of long-acting insulin analogues to the World Health Organisation’s Model List of Essential Medicines, citing price as a key factor.
Drug industry concerns about natural disasters are driving demand for ‘storage-only’ stability testing according to Intertek, which has announced plans to expand its UK lab.
Hovione has launched its first clinical trial and has already set sights on a second as the CDMO hopes to establish licensing partnership with pharma, says VP.
LSNE Contract Manufacturing has signed a manufacturing supply agreement with Selecta Biosciences, Inc. through which the CDMO will advance Selecta’s lead candidate, SEL-212.
Enhanced clinical trial design legislation proposes an alternative to the Right to Try Act – both of which address the FDA's current compassionate use program.
The US FDA has banned APIs made by Changzhou Jintan Qianyao Pharmaceutical Raw Materials after staff told inspectors their quality testing plans were “in their heads.”
The extended partnership provides CROS NT customers access to Medidata’s electronic data capture (EDC) solution as well as its randomization and trial supply management system (RTSM).
The US FDA has refused to reapprove Sun Pharma Advanced Research LTD’s epilepsy drug Elepsia XR (levetiracetam) citing problems at its plant in Halol, India.
The University of Birmingham has developed a cell-penetrating peptide it claims could be used to make eye drop versions of age-related macular degeneration drugs currently delivered by injection.
SGS has completed a Phase I clinical trial of a new influenza virus strain in healthy volunteers and has increased capacity at its Mississauga, Canada-based laboratory.
Evotec AG has received a payment of approximately €5m ($5.62m) as part of its strategic alliance with Bayer – which the company says is “well on track and very successful.”
Proposed amendments to the European Medicines Agency’s (EMA) access to documents policy have been criticised by medicines watchdogs, including not-for-profit Health Action International and Prescrire.
The High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement of DSM Sinochem Pharmaceuticals’ enzyme-based antibiotic production IP.
Burkholderia cepacia contamination is a risk for drug makers according to the US FDA, which says only rigorous testing can ensure the safety of non-sterile, water-based products.
Pharma and CMOs must start addressing their serialization needs ahead of 2019’s EU Falsified Medicines Directive, says Tracelink which is bringing its supply chain event NEXUS to Barcelona next month.
Charles River Laboratories International, Inc. has partnered with OcellO to expand its PDX model capabilities and has made several additions to its online Tumor Model Compendium.
Contract research organizations (CROs) continue to see high instances of turnover, which can lead to delayed timelines and sponsor scrutiny, according to a recent survey.
AB Science’s candidate cancer drug Masitinib (masitinib) should not be approved according to an EMA committee, which cited concerns about data and failings identified in a 2015 trial.
Merck & Co and Aduro Biotech have announced plans to test Keytruda combined with CRS-207 in patients suffering malignant pleural mesothelioma as a result of exposure to asbestos.
